Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial.
about
Thyroid hormone replacement for subclinical hypothyroidismPhysiopathological aspects of the subclinical alterations of thyroid function associated with acute coronary syndromesHypothyroidism in coronary heart disease and its relation to selected risk factorsThyroid functional disease: an under-recognized cardiovascular risk factor in kidney disease patientsTreatment-resistant depression and mortality after acute coronary syndrome.Subclinical hypothyroidism: to treat or not to treat, that is the question! A systematic review with meta-analysis on lipid profile.Endothelial function is not changed during short-term withdrawal of thyroxine in patients with differentiated thyroid cancer and low cardiovascular riskSubclinical hypothyroidism and risk for incident ischemic stroke among postmenopausal womenEffects of thyroid dysfunction on lipid profile.Serum Phospholipase A2-IIA, hs-CRP, and Lipids in Women With Subclinical HypothyroidismSalivary C-Reactive Protein in Hashimoto's Thyroiditis and Subacute ThyroiditisThe role of serum C-reactive protein measured by high-sensitive method in thyroid disease.Mechanism of subclinical hypothyroidism accelerating endothelial dysfunction (Review)Association between plasma homocysteine status and hypothyroidism: a meta-analysisLipid abnormalities and cardiometabolic risk in patients with overt and subclinical thyroid disease.Improvement of blood inflammatory marker levels in patients with hypothyroidism under levothyroxine treatment.Prevalence of Subclinical Hypothyroidism among Patients with Acute Myocardial InfarctionRole of surrogate markers of atherosclerosis in clinical and subclinical thyroidismRelationship between Diabetic Retinopathy and Subclinical Hypothyroidism: a meta-analysisPresence of thyrotropin receptor in hepatocytes: not a case of illegitimate transcriptionHypothyroidism in the elderly: diagnosis and managementNative Magnetic Resonance T1-Mapping Identifies Diffuse Myocardial Injury in HypothyroidismAssociations of triiodothyronine levels with carotid atherosclerosis and arterial stiffness in hemodialysis patientsAre hsCRP Levels and LDL/HDL Ratio Better and Early Markers to Unmask Onset of Dyslipidemia and Inflammation in Asymptomatic Subclinical Hypothyroidism?Study on Subclinical Hypothyroidism and its Association with Various Inflammatory Markers.No evidence of association between subclinical thyroid disorders and common carotid intima medial thickness or atherosclerotic plaque.Cardiac Risk Markers and Response to Depression Treatment in Patients With Coronary Heart Disease.Significant role of serum CRP in differentiating inflammatory from non-inflammatory causes of thyrotoxicosisHypothyroidism as a risk factor for development of cardiovascular disease in patients with rheumatoid arthritis.Altered fructosamine and lipid fractions in subclinical hypothyroidism.Serum resistin and high sensitive CRP levels in patients with subclinical hypothyroidism before and after L-thyroxine therapyCardiovascular risk with subclinical hyperthyroidism and hypothyroidism: pathophysiology and management.Association between primary hypothyroidism and metabolic syndrome and the role of C reactive protein: a cross-sectional study from South IndiaClinical significance of determining plasma homocysteine: case-control study on arterial and venous thrombotic patients.Cerebral venous sinus thrombosis with autoimmune thyroiditisEffects of folic acid plus levothyroxine on serum homocysteine level in hypothyroidism.Relation of hypothyroidism and incident atrial fibrillation (from the Framingham Heart Study).Serum Lipid Transfer Proteins in Hypothyreotic Patients Are Inversely Correlated with Thyroid-Stimulating Hormone (TSH) Levels.Thyroid Function and High-Sensitivity C-Reactive Protein in Cross-Sectional Results from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil): Effect of Adiposity and Insulin Resistance.Thyroid hormone analogs for the treatment of dyslipidemia: past, present, and future.
P2860
Q22918881-8FC42D40-6F29-4F09-A433-C3871AB3C187Q26827308-2EA923AD-9E65-4296-8977-A82CF6305085Q28219425-820666A7-6470-4103-9AE6-F7183E516ACAQ28647790-C76B4D6C-A32B-4E4D-B957-B92B08AA5535Q33418538-08B57AAA-DD99-4F9E-BE7D-5B23010AB67DQ33674697-0A4D5C71-0F84-4799-A2A0-24AD36A15432Q33892212-D358595D-484B-49EE-906A-2E2D47201B07Q33931480-404A0F4E-A869-4F35-98EB-A43FE33DFE3BQ34191474-973D4F95-BD1B-4E27-BB59-F93F46A73580Q34197005-AC6EE03E-ABA5-41E4-A976-4BA0C0D83801Q34340372-1DABEDD9-F556-4778-849C-56A6FAA1DAEEQ34573865-FC9AEF70-FCA2-4579-A13B-423C7513A616Q34585374-26A6C89E-AFFE-46AA-9E62-F4C693F3620DQ34770181-A7B484B6-75B1-4401-B924-D17003691D15Q35116881-DF526C3F-FF9D-4836-8BB4-EEA883AA9D0FQ35671236-1E2FBD0D-C778-4A02-8C2C-84BD9AE03C4EQ35684643-CB44215F-2E05-48D9-AB09-9DC1A48EC5CAQ35810383-0B3DADF5-092D-4385-AA3A-E8D0837331D4Q35866161-B2E07EB8-7DEB-470A-9288-36645D0896D0Q35889144-951D245B-5F62-4503-8978-EADE5FEE89EEQ35922096-F65FC4B9-BB63-4A4C-AE89-3814852CDDFAQ35952919-7DA18FD3-380E-4E1D-ADB0-D1BD5952192AQ35983469-6D7ACD5B-E6DA-4D8D-9E93-FF18E9702338Q36080014-394C7D35-E42F-4D55-88D1-B11E71A6E131Q36343406-9296E4F9-8B45-493A-88BC-1B946F882985Q36385039-15DE138F-D79C-4D0B-B458-1D8BE70A07E9Q36418491-4B29FE76-6023-4F5B-BEE3-2C4A09B6906DQ36436529-0ED1294C-B161-451A-8AB4-2159D4C72DEFQ36456316-EA63AE08-1F8D-4ABD-AD82-3E2EB6B276E0Q36622448-5ACBF45B-7D5C-4CD4-8C7C-AC6DC6C91636Q36772021-268161A4-DA61-4C82-97CF-2DD87F78031FQ36929375-1AE86398-5E30-4611-A537-C28949E5325BQ37127330-78CA3662-FD9D-45F8-9F39-08ADF0012287Q37277006-01009327-D69A-4EC8-9C17-4D8F92587003Q37314573-F4F7F71E-C98B-46F9-A742-805A142DE089Q37389388-D5718F0C-1CA4-49DF-AA05-E76209358EABQ37403263-60B5C8A4-9134-49D9-89C3-0C7686D3429DQ37485394-B6815739-52FE-42DB-88CD-A98C0BB8BCECQ37562998-5AAE9721-BE74-447C-ABBD-AE9675FA1C6FQ38684663-C4FB4D90-EF6C-4697-9000-62D976808E54
P2860
Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Elevated C-reactive protein an ...... ind, placebo-controlled trial.
@en
Elevated C-reactive protein an ...... ind, placebo-controlled trial.
@nl
type
label
Elevated C-reactive protein an ...... ind, placebo-controlled trial.
@en
Elevated C-reactive protein an ...... ind, placebo-controlled trial.
@nl
prefLabel
Elevated C-reactive protein an ...... ind, placebo-controlled trial.
@en
Elevated C-reactive protein an ...... ind, placebo-controlled trial.
@nl
P2093
P1433
P1476
Elevated C-reactive protein an ...... lind, placebo-controlled trial
@en
P2093
Beat Müller
Christian Meier
Jean Jacques Staub
Merih Guglielmetti
Peter R Huber
Walter Riesen
P304
P356
10.1016/S0021-9150(02)00372-6
P577
2003-02-01T00:00:00Z